A physician-led gateway to Japan-based precision imaging, inflammation assessment, additional tests as appropriate, and a physician-reviewed next-step report in Tokyo.
If screening raises a concern, specialist evaluation is prioritized. Screening is not a confirmed diagnosis. Any further medical steps are organized individually by the physician after review.
Cellforce One Clinic Tokyo is not positioned as a low-cost medical trip or a direct procedure counter. The first value is organized access: imaging, blood markers, inflammation context, cancer-risk triage, physician interpretation, and a clear next-step plan.
MRI, DWI, MRA, CT, blood tests, inflammation markers, cell-activity and energy-metabolism related markers, additional tests as appropriate, and lifestyle data are selected based on history and goals.
Findings are organized into a physician-reviewed route: what is reassuring, what needs follow-up, and what should be checked before any advanced option is discussed.
Unexplained inflammation, suspected cancer-related findings, infection, thrombosis risk, or acute symptoms move the patient to additional testing or specialist care first.
Japan has strong diagnostic imaging availability by international comparison. For international patients, the harder part is selecting the right test, understanding the result, and knowing when to stop, refer, monitor, or proceed.
Approximate foreign visitors to Japan in 2024, according to the Prime Minister's Office of Japan.
OECD reports Japan has high per-capita availability of CT scanners and MRI units.
Japan's Medical Stay Visa framework includes full medical check-ups and medical examinations.
Medical cost and treatment burden are not determined by the disease name alone. They can change depending on when a concern is found, which tests or treatments are needed, and whether repeated visits or hospitalization become necessary.
Research across multiple cancer types has reported that healthcare costs tend to be higher when cancer is diagnosed at a later stage. Japanese studies also report that first-year medical resource use differs by cancer type and stage.
That is why the Gateway starts by organizing your current status, prior records, symptoms, imaging needs, and risk signals before a concern becomes urgent.
A small concern, family history, prior abnormal result, or travel window can be enough reason to organize what should be checked next.
The purpose is not to add every test. It is to choose blood tests, imaging, and cancer-risk screening based on history, goals, and physician review.
Results are used to decide whether to monitor, add testing, refer to a specialist, or discuss upper options after physician explanation.
The Gateway combines imaging and laboratory layers. It does not treat one biomarker as a final answer; each result is interpreted with symptoms, history, medications, prior records, and travel constraints.
Brain, vascular, lung, joint, spine, and whole-body routes may be considered depending on risk, age, family history, symptoms, and prior results.
Inflammation is reviewed as a context marker. High or unexplained inflammation is a reason to investigate further, not a reason to rush ahead.
Cell-activity and energy-metabolism related markers may help frame immune, aging-related, or inflammation signals. These tests support discussion; they do not confirm diagnosis alone.
After the Tokyo visit, the team can organize follow-up review, nutrition and lifestyle priorities, local-physician questions, and return-visit planning.
A premium gateway should not rush every patient into a procedure. It should separate patients who can consider next options from patients who need additional workup first.
No major stop signal is found in the reviewed scope. Next steps may be discussed by the physician when appropriate.
Mild inflammation, glucose metabolism, sleep, nutrition, or vascular risk issues may be addressed before advanced options are revisited.
Unreviewed imaging findings, abnormal cancer-risk screening, unexplained anemia, or significant inflammation move the plan to additional tests or specialist consultation.
Suspected active cancer, acute symptoms, infection, thrombosis risk, or other major findings should be handled through specialist or standard medical care first.
These are reference prices for planning. Imaging facility fees, test selection, interpreter support, family briefings, and specialist access vary by case and are quoted after pre-consultation.
Blood markers, inflammation review, additional tests as appropriate, physician review, and a concise route report.
Gateway plus conditioning review, detailed report, multilingual explanation support, and return-visit planning.
Imaging credit, brain / cancer-risk / inflammation review, specialist-access planning, and family-facing explanation.
Family screening coordination, imaging and blood-test planning, specialist access, and multilingual report support.
This page is for screening and interpretation; it does not sell any procedure. Any further medical steps are organized individually by the physician after review, informed consent, and quality-document review.
No. This page is for screening and interpretation. Any further medical steps are organized individually by the physician after review and appropriate consent.
The Gateway checks for reasons to pause first, including unexplained inflammation, cancer-related findings, infection risk, thrombosis risk, medication issues, or acute symptoms. Any further steps are organized individually by the physician after review.
No. Imaging, blood tests, and additional tests as appropriate can help identify findings that may need follow-up, but confirmed diagnosis and treatment planning require appropriate medical evaluation and, when needed, specialist care.
Japan's Medical Stay Visa framework includes medical check-ups and examinations, but visa decisions and required documents depend on nationality, route, guarantor, and the planned medical services.
Japan inbound context: Prime Minister's Office of Japan, Ministerial Council on the Promotion of Japan as a Tourism-Oriented Country, March 18, 2025.
Diagnostic technology context: OECD Health at a Glance 2023, diagnostic technologies section.
Medical stay framework: Ministry of Foreign Affairs of Japan, Visa for Medical Stay.
Health expenditure context: OECD Health at a Glance 2025. This is used as background, not as a direct price comparison for this program.
Cancer cost context: BMC Health Services Research 2022, later-stage cancer diagnosis and healthcare costs; Japanese cancer resource-use studies are used only as burden context, not as a promise that screening reduces cost.
Inflammatory aging context: Nat Aging 2021 iAge paper. Inflammation-related markers are treated as association signals, not as a standalone aging diagnosis.
Send your purpose, medical history, available reports, preferred language, and planned travel dates. The clinic will help organize a suitable Gateway route before your Tokyo visit.
Cellforce One Clinic Tokyo / Ginza 6-chome / Self-funded medical services.
